Stock ACCD ACCOLADE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Accolade, Inc.

Equities

ACCD

US00437E1029

Healthcare Facilities & Services

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
7.89 USD -14.15% Intraday chart for Accolade, Inc. -13.58% -34.30%
Apr. 26 Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating MT
Apr. 25 Transcript : Accolade, Inc., Q4 2024 Earnings Call, Apr 25, 2024

Valuation

Fiscal Period: February 2021 2022 2023 2024 2025 2026 2027
Capitalization 1 2,452 1,204 808.7 793.4 618.2 - -
Enterprise Value (EV) 1 2,018 1,119 769.9 793.4 449.7 441.6 431
P/E ratio -25.8 x -9.32 x -1.72 x -7.71 x -6.36 x -7.13 x -9.83 x
Yield - - - - - - -
Capitalization / Revenue 14.4 x 3.88 x 2.23 x 1.92 x 1.26 x 1.07 x 0.9 x
EV / Revenue 11.8 x 3.61 x 2.12 x 1.92 x 0.92 x 0.77 x 0.63 x
EV / EBITDA -74.9 x -26.4 x -21.1 x -106 x 27.7 x 12.3 x 6.2 x
EV / FCF -74.1 x -17.2 x -18 x - 18.5 x 11.8 x 8.66 x
FCF Yield -1.35% -5.8% -5.56% - 5.4% 8.46% 11.6%
Price to Book 6.32 x 1.41 x 1.67 x - 1.45 x 1.46 x 1.39 x
Nbr of stocks (in thousands) 55,321 66,958 72,787 77,408 78,357 - -
Reference price 2 44.32 17.98 11.11 10.25 7.890 7.890 7.890
Announcement Date 5/5/21 4/28/22 4/27/23 4/25/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: February 2020 2021 2022 2023 2024 2025 2026 2027
Net sales 1 132.5 170.4 310 363.1 414.3 490.9 575.5 687.2
EBITDA 1 - -26.94 -42.38 -36.5 -7.491 16.25 35.98 69.5
EBIT 1 - -46.78 -125.7 -463.5 -114.5 -97.1 -88.85 -62.05
Operating Margin - -27.46% -40.55% -127.64% -27.63% -19.78% -15.44% -9.03%
Earnings before Tax (EBT) 1 - -50.65 -128.8 -463.3 -98.57 -91.38 -84.23 -58.63
Net income 1 - -50.65 -123.1 -459.6 -99.8 -93.76 -83.45 -61.59
Net margin - -29.73% -39.71% -126.58% -24.09% -19.1% -14.5% -8.96%
EPS 2 -9.130 -1.720 -1.930 -6.450 -1.330 -1.241 -1.107 -0.8025
Free Cash Flow 1 - -27.22 -64.87 -42.81 - 24.3 37.37 49.8
FCF margin - -15.98% -20.92% -11.79% - 4.95% 6.49% 7.25%
FCF Conversion (EBITDA) - - - - - 149.58% 103.84% 71.65%
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 6/16/20 5/5/21 4/28/22 4/27/23 4/25/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: February 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4 2026 Q1
Net sales 1 83.45 93.76 85.53 87.64 90.95 99.02 93.23 96.86 99.37 124.8 105.4 113.2 116.8 154.9 124.3
EBITDA 1 -11.94 1.818 -15.37 -13.75 -10.22 2.832 -12.58 -8.764 -4.626 18.48 -9.222 -5.793 1.446 30.68 -5.7
EBIT 1 -41.88 -29.81 -346 -45.91 -40.38 -31.19 -39.63 -35.21 -31.72 -7.897 -37.46 -35.15 -27.21 1.496 -35.9
Operating Margin -50.19% -31.8% -404.59% -52.38% -44.4% -31.49% -42.51% -36.35% -31.92% -6.33% -35.55% -31.04% -23.3% 0.97% -28.89%
Earnings before Tax (EBT) 1 25.83 -30.69 -346.7 -46.27 -39.8 -30.48 -38.32 -32.74 -20.73 -6.778 -35.84 -33.22 -25.21 1.93 -35.4
Net income 1 22.5 -34.56 -342.8 -46.52 -39.87 -30.43 -38.41 -32.82 -21.06 -7.507 -36.82 -34.16 -25.91 1.737 -36.1
Net margin 26.97% -36.86% -400.83% -53.08% -43.84% -30.73% -41.2% -33.89% -21.2% -6.01% -34.94% -30.17% -22.19% 1.12% -29.05%
EPS 2 0.3100 -0.5100 -4.920 -0.6600 -0.5600 -0.4200 -0.5200 -0.4300 -0.2800 -0.1000 -0.4831 -0.4404 -0.3413 0.0242 -0.4488
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/10/22 4/28/22 6/30/22 10/6/22 1/9/23 4/27/23 6/29/23 10/4/23 1/8/24 4/25/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: February 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 - - - - - - - -
Net Cash position 1 - 434 85.2 38.8 - 169 177 187
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -27.2 -64.9 -42.8 - 24.3 37.4 49.8
ROE (net income / shareholders' equity) - -72.5% -19.8% -69.1% - -20.3% -18% -14%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - 7.020 12.80 6.650 - 5.440 5.390 5.690
Cash Flow per Share 2 - -0.8600 -0.9800 -0.5700 - 0.4400 0.6400 -
Capex 1 - 1.99 2.52 2.11 - 5.23 6.17 3.5
Capex / Sales - 1.17% 0.81% 0.58% - 1.07% 1.07% 0.51%
Announcement Date 6/16/20 5/5/21 4/28/22 4/27/23 4/25/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Accolade, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
7.89 USD
Average target price
13.47 USD
Spread / Average Target
+70.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
ACCOLADE, INC. Stock Accolade, Inc.
-34.30% 618M
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.92% 29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. ACCD Stock
  4. Financials Accolade, Inc.